摘要
目的探讨血清β2-微球蛋白在前列腺癌患者内分泌治疗前后表达差异性及与血清前列腺特异抗原相关性,为前列腺癌的诊断和预后治疗的检测提供依据。方法选取前列腺癌患者35例以及前列腺增生患者和正常人各35例。收集样本血清并采用放射性放射免疫法检测血清β2-微球蛋白和血清前列腺特异抗原的表达。分析血清β2-微球蛋白在前列腺癌患者内分泌治疗前后表达差异性及与血清前列腺特异抗原相关性。应用pearson相关性分析。结果前列腺癌患者的血清β2-微球蛋白及血清前列腺特异抗原水平明显高于前列腺增生患者和正常人。前列腺增生患者的血清β2-微球蛋白水平与正常人无明显差异。前列腺癌患者的血清β2-微球蛋白与血清前列腺特异抗原水平呈正相关。前列腺癌患者在治疗1个月,3个月,4个月后血清β2-微球蛋白及血清前列腺特异抗原水平不断降低,但在少数癌细胞发生转移的患者中升高,且各个时间段均呈正相关。结论血清β2-微球蛋白水平可以作为前列腺癌患者临床诊断和内分泌治疗效果的监测依据以及作为区分前列腺癌和前列腺增生的依据。前列腺癌患者的血清β2-微球蛋白与血清前列腺特异抗原水平呈正相关。
Objective To investigate the difference of serum β2-microglobulin expression in prostate cancer patients before and after endocrine therapy and its correlation with serum PSA,so as to provide evidence for the diagnosis and prognosis treatment of prostate cancer. Methods 35 cases of prostate cancer and 35 cases of benign prostatic hyperplasia and normal subjects were selected. Serum samples were collected and radioimmunoassay was used to detect serum β2-microglobulin and serum prostate specific antigen. Serum β2-microglobulin expression differences and serum prostate specific antigen in patients with prostate cancer before and after the endocrine therapy was analyzed. Pearson correlation analysis was applied. Results Prostate cancer patients serum β2-microglobulin and serum prostate-specific antigen levels were significantly higher than in patients with benign prostatic hyperplasia and normal patiernts. Serum β2-microglobulin levels in patients with benign prostatic hyperplasia and normal patiernts had no significant difference. Serum β2-microglobulin in prostate cancer patients was positively correlated with serum PSA level.Prostate cancer patients in the treatment of 1 month,3 months,4 months after the serum β2-microglobulin and serum prostate-specific antigen levels continue to decline,but in a small number of cancer cells in patients with metastasis increased,and each time period was positively correlated. Conclusion Serum β2-microglobulin levels can be used as a basis for the clinical diagnosis and endocrine treatment of prostate cancer patients and as a basis for distinguishing between prostate cancer and benign prostatic hyperplasia. Serum β2-microglobulin in prostate cancer patients is positively correlated with serum PSA level.
作者
李业山
LI Yeshan(China National Petroleum Corporation Central Hospital,Langfang,06500)
出处
《实用癌症杂志》
2018年第9期1418-1420,共3页
The Practical Journal of Cancer
